diagnost tool
us dtc test undergo makeov
downgrad hold lower pt
disappoint underli trend direct-to-consum dtc
genet test larg us market seem find new normal growth
interest unfortun lack convict trend revert back
meaning growth news event even within last two week alon give us paus
manag chang strateg shift helix closur arival among
other indic call see ancestri market us matur
like level next coupl year buy-rat thesi underpin
us-bas dtc test would grow double-digit growth next sever year
longer longer convict thu downgrad buy
hold remov one top pick lower pt
acknowledg could potenti look attract valu investor present level
rev possibl even larger compani look tuck-in
recap rev y/i narrowli top our/street
ep roughli line our/street
gm miss due product mix lower royalti payment
ancestri came y/i estim
manag indic expect season amplifi consum wait
purchas ahead major holiday take advanc heavili discount test
absent heavi discount advertis know demand look like
said guarante see recoveri opinion molecular
collect rev declin y/i though top lower
full year guid posit surpris applaud manag initi full year
revenu guid y/i bracket street
prior believ first compani histori manag
indic provid fy guid base assum largest dtc custom
contractu minimum differ year expect custom order
minimum prior year order meet surg demand
guid initi ep guid
prior think lower ep guid versu us/street like
contempl come prior estim lower royalti
payment rel prior estim guid rev
y/i prior
healthi nevada project expand healthi nevada project highlight
prior ilmn/osur report announc expand popul genom
program la vega add potenti addit particip
nevada project enrol particip sinc incept year ago octob
announc plan expand program addit peopl nevada
new commun across us know estim increment
patient would result revenu thu would take major
ramp new pop seq initi across us move needl view
lower year estim page model commentari
buy
price close busi may
orasur domin provid saliva collect
devic genet test leader oral fluid
diagnost rapid point care hiv hcv test
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
model chang factor modest revenu beat higher guid rel
think rais revenu estim vs guid
lower gm estim
lower ep estim prior compani guid
lower revenu estim
lower revenu estim lower
ep estim lower ep estim
pt valuat framework new price target base use multipl
revenu estim discount back two year discount
rate ad net cash posit balanc sheet
formerli pt use multipl revenu estim
discount back two year discount rate assign lower multipl given
lack visibl growth rate dtc test compani overal growth
rate revenu gross margin ep think molecular collect revenu
continu grow even despit disappoint dtc test
encourag promis grow microbiom test futur
microbiom revenu revenu
go know labcorp result
dtc test grew expect busi flatten rest
year given like slowdown possibl ancestri mention
strateg shift helix lh indic call expect flat slightli
y/i growth dtc genet test lower array guid
flat y/i lsd cite cautiou view dtc market suspect
reduc test discount lower demand
product lower heavi tv ad spend word clear us
intent term need meaning expand alreadi larg
databas consent custom exce million peopl
stock price cover compani mention
laboratori corpor america hold lh nyse hold
hold buy target price may
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
hold buy target price may
diagnost tool
hold buy target price may
diagnost tool
hold buy target price may
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin may et
date time product may et
price target base use multipl revenu estim discount back two year
discount rate ad net cash posit balanc sheet
pt use multipl adj ep estim
laboratori corpor america hold lh
pt use multipl adj ep estim
risk achiev target price valuat
regulatori risk exist new test indic delay denial approv would neg affect compani commerci risk
exist product reimburs competit continu weak economi could inhibit growth orasur drug
abus test busi risk associ intern sale infecti diseas product risk relat fund hiv
particularli unit state competit risk gener hiv product dna genotek subsidiari larg
custom failur continu work would advers impact busi
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
hold buy target price may
diagnost tool
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
